Drug news
Janssen Cilag withdraws application at EMA for Velcade in Follicular Lymphoma
Janssen Cilag has withdrawn its application for EU approval for the use of Velcade (bortezomib) in combination with rituximab as a treatment for patients with relapsed Follicular non-Hodgkin Lymphoma.
The European Medicines Agency said it had been formally notified by the company that it was withdrawing the application because the Committee for Medicinal Products for Human Use indicated that the data underpinning its application do not support a positive benefit-risk balance.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.